After years of plodding work, mostly by pharma firms, several are pushing products to the finish line for liver cancer, also known as hepatocellular carcinoma, but handicapping their chances is tricky. "They're all going to struggle to unseat Nexavar [in first-line therapy]" from Onyx Pharmaceuticals Inc., said Marcus Hoyle, oncology analyst for Decision Resources. Read More
